Pacira BioSciences Inc (PCRX)
26.05
-0.28
(-1.06%)
USD |
NASDAQ |
Apr 29, 16:00
26.07
+0.02
(+0.08%)
After-Hours: 20:00
Pacira BioSciences Price to Book Value: 1.392 for April 29, 2024
Price to Book Value Chart
Historical Price to Book Value Data
Date | Value |
---|---|
April 29, 2024 | 1.392 |
April 26, 2024 | 1.407 |
April 25, 2024 | 1.363 |
April 24, 2024 | 1.384 |
April 23, 2024 | 1.433 |
April 22, 2024 | 1.395 |
April 19, 2024 | 1.403 |
April 18, 2024 | 1.395 |
April 17, 2024 | 1.431 |
April 16, 2024 | 1.436 |
April 15, 2024 | 1.418 |
April 12, 2024 | 1.434 |
April 11, 2024 | 1.462 |
April 10, 2024 | 1.487 |
April 09, 2024 | 1.524 |
April 08, 2024 | 1.522 |
April 05, 2024 | 1.505 |
April 04, 2024 | 1.518 |
April 03, 2024 | 1.550 |
April 02, 2024 | 1.524 |
April 01, 2024 | 1.558 |
March 28, 2024 | 1.562 |
March 27, 2024 | 1.552 |
March 26, 2024 | 1.524 |
March 25, 2024 | 1.562 |
Date | Value |
---|---|
March 22, 2024 | 1.532 |
March 21, 2024 | 1.565 |
March 20, 2024 | 1.604 |
March 19, 2024 | 1.575 |
March 18, 2024 | 1.565 |
March 15, 2024 | 1.572 |
March 14, 2024 | 1.564 |
March 13, 2024 | 1.619 |
March 12, 2024 | 1.633 |
March 11, 2024 | 1.658 |
March 08, 2024 | 1.679 |
March 07, 2024 | 1.637 |
March 06, 2024 | 1.609 |
March 05, 2024 | 1.573 |
March 04, 2024 | 1.560 |
March 01, 2024 | 1.542 |
February 29, 2024 | 1.588 |
February 28, 2024 | 1.598 |
February 27, 2024 | 1.595 |
February 26, 2024 | 1.589 |
February 23, 2024 | 1.605 |
February 22, 2024 | 1.601 |
February 21, 2024 | 1.586 |
February 20, 2024 | 1.595 |
February 16, 2024 | 1.553 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.363
Minimum
Apr 25 2024
6.938
Maximum
Sep 02 2020
3.791
Average
3.843
Median
Aug 27 2021
Price to Book Value Benchmarks
Dynavax Technologies Corp | 2.381 |
Arbutus Biopharma Corp | 4.724 |
Chimerix Inc | 0.4319 |
Karyopharm Therapeutics Inc | -- |
FibroGen Inc | -- |
Price to Book Value Related Metrics
PE Ratio | 31.39 |
PS Ratio | 2.113 |
PEG Ratio | 0.1871 |
Price to Free Cash Flow | 10.22 |
Price | 26.05 |
Earnings Yield | 3.19% |
Market Cap | 1.211B |
PEGY Ratio | 0.1871 |
Operating PE Ratio | 16.33 |
Normalized PE Ratio | 23.03 |